Amyloid β-Peptide (1-42) (human) NEW
Price | $28 |
Package | 1box |
Min. Order: | 1box |
Supply Ability: | 20000 |
Update Time: | 2024-05-15 |
Product Details
Product Name: Amyloid β-Peptide (1-42) (human) | CAS No.: 107761-42-2 |
Min. Order: 1box | Purity: 99% |
Supply Ability: 20000 | Release date: 2024/05/15 |
Molecular Formula C203H311N55O60S
Molecular Weight 4514.04000
Exact Mass 4511.27000
PSA 1840.49000
LogP 1.35150
Storage condition ?20°C
Company Profile Introduction
Shanghai Getian Industrial Co.,Ltd is a leading enterprise committed to providing quality products and efficient logistics services. We are proud to introduce a range of products with excellent quality, and the industrial materials are subject to strict quality control to ensure that the high standards of our customers are met.
We have pharmaceutical raw material production factory and reagent research and development center. We now have a complete product line. In addition, we have developed and produced tens of thousands of reagents. We are complemented by a custom synthesis business of various organic compounds. We can synthesize almost any chemical.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$40.00/1Box |
VIP1Y
|
Qingdao Xinli Technology Development Co., Ltd.
|
2024-07-25 | |
$70.00/1box |
VIP6Y
|
Shanghai Longyu Biotechnology Co., Ltd.
|
2024-06-27 | |
$80.00/1box |
VIP1Y
|
Strong peptide cross-border e-commerce Co. LTD
|
2024-05-24 | |
$0.00/1KG |
VIP1Y
|
Shanghai Affida new material science and technology center
|
2024-04-26 | |
$10.00/1kg |
VIP1Y
|
Wuhan Xinhao Biotechnology Co., Ltd
|
2024-02-22 | |
$25.00/10mg |
Hebei Yime New Material Technology Co., Ltd.
|
2024-02-01 | ||
$25.00/1box |
VIP1Y
|
Sigma Audley
|
2024-01-17 | |
$90.00/1box |
VIP2Y
|
Hebei Xunou new energy Technology Co., LTD
|
2023-12-05 | |
$0.00/1KG |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-11-30 | ||
$0.00/1kg |
Hebei Xinsheng New Material Technology Co., LTD.
|
2023-10-25 |
- Since: 2024-01-19
- Address: Hong Kong
INQUIRY